ENDURE: Engagement with the Novel Therapies and Decision Making Through Breast Cancer Education March 9th 2017

March 9, 2017

The goal of this educational activity to improve healthcare providers’ knowledge of a new novel treatment strategy for patients with breast cancer.  

Learning Objectives

After completing this activity, the participant should be better able to:

  • Review current research on the use of CDK 4/6 inhibitors for breast cancer patients, including  pre-clinical data, biomarker targets and sensitivity and resistance mechanisms
  • Discuss the MOA of CDK 4/6 inhibitors
  • Review clinical trial data on CDK 4/6 inhibitors, including efficacy and safety data
  • Identify appropriate patient selection for the use of CDK 4/6 inhibitors
  • Review the toxicity profiles of CDK 4/6 inhibitors
  • Apply strategies to manage neutropenia and other adverse events
  • Discuss existing and emerging clinical trial data associated with adverse events of combination  therapies using CDK 4/6 inhibitors
  • Discuss ways to enhance clinician/patient communication to improve patient outcomes
  • Apply shared decision-making strategies in the management of patients with breast cancer
Course summary
Available credit: 
  • 1.00 ACPE - Pharmacist
  • 1.00 ANCC
  • 1.00 JA Credit - AH
Registration Opens: 
Registration Expires: 
Activity Starts: 
03/09/2017 - 5:30pm EST
Activity Ends: 
03/09/2017 - 5:30pm EST
Scully-Welsh Cancer Center
741 First Colonial Road in the Marketplace at Hilltop
Walker Conference Room,3555 10th Ct
Vero Beach, FL
United States

P.Kelly Marcom, MD

Linda Sutton, MD

Kerri Dalton, MSN, RN, AOCNS

Melanie Watson, MSN, RN

Richard Finn, MD

Donna Topping PharmD


Available Credit

  • 1.00 ACPE - Pharmacist
  • 1.00 ANCC
  • 1.00 JA Credit - AH
Please login or register to take this course.